elvitegravir (vitekta) Report issue

Small molecule Approved FDA Fast Track FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor used in combination with cobicistat, emtricitabine and tenofovir alafenamid (GENVOYA®) for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection.   NCATS

Chemistry

  • SMILES: COC1=CC2=C(C=C1CC3=CC=CC(Cl)=C3F)C(=O)C(=CN2[C@H](CO)C(C)C)C(O)=O
  • InChIKey: JUZYLCPPVHEVSV-LJQANCHMSA-N
  • Mol. Mass: 447.884
  • ALogP: 4.28
  • ChEMBL Molecule:
    elvitegravir  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( emtricitabine (emtriva), tenofovir alafenamide (genvoya), cobicistat (stribild), elvitegravir (vitekta) - other name: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide )
|
( tenofovir (viread), emtricitabine (emtriva), cobicistat (stribild), elvitegravir (vitekta) - other name: cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate )

Alternative names

6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | elvitegravir | elvitégravir | elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide | elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate | evg | gs9137 | gs 9137 | gs-9137 | jtk303 | jtk 303 | jtk-303 | vitekta

Organizations (46)

Research & Development (45)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

HIV Infections

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Antiretroviral Therapy, Highly Active (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 1/Phase 2)

Healthy Volunteers (Phase 4)

Hepatitis B (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Herpes Simplex (Phase 1)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV Infections ()

Insulin Resistance (Phase 1)

Mitochondrial Diseases (Phase 1/Phase 2)

Patient Compliance (Phase 4)

Sleep Wake Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 52
  • # of Trial Organizations: 45

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue